Argent BioPharma Limited (LON:MXC – Get Free Report)’s share price shot up 4.8% on Friday . The company traded as high as GBX 22 ($0.29) and last traded at GBX 22 ($0.29). 264 shares traded hands during trading, a decline of 99% from the average session volume of 26,353 shares. The stock had previously closed at GBX 21 ($0.27).
Argent BioPharma Stock Performance
The firm has a fifty day moving average of GBX 22 and a 200-day moving average of GBX 21.64. The stock has a market capitalization of £9.65 million, a price-to-earnings ratio of -13.25 and a beta of 1.03.
Argent BioPharma Company Profile
MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
Featured Stories
- Five stocks we like better than Argent BioPharma
- What is the FTSE 100 index?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Comparing and Trading High PE Ratio Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Argent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.